HKG: 2315

Company Deals

Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development

Fineline Cube Jul 6, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with...

Company Drug

Biocytogen Pharmaceuticals Receives CNIPA Patent for RenMab Human Antibody Mice Platform

Fineline Cube Jun 21, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced receiving a prestigious patent award...

Company Deals

Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform

Fineline Cube Mar 9, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...

Company Deals

Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform

Fineline Cube Mar 9, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally